| 84.47 Data as of May 24 |  +9.80 / +13.12%Today’s Change | 42.47 Today|||52-Week Range 87.50 | +41.33% Year-to-Date |
| Valeant Pharmaceuticals International Reaches New 52-Week High (VRX) May 24 / TheStreet.com | Wider-Than-Expected Loss at Anacor - Analyst Blog May 13 / Zacks.com |
| Favorable Verdict for Mylan - Analyst Blog May 22 / Zacks.com | Actavis: What it's like to join the Fortune 500 May 10 / Fortune |
| Actavis: The latest Fortune 500 company to "leave" the U.S. for tax reasons May 21 / Fortune |
| Previous close | 74.67 |
| Today’s open | 74.30 |
| Day’s range | 73.25 - 87.50 |
| Volume | 10,383,614 |
| Average volume (3 months) | 1,541,497 |
| Market cap | $25.7B |
| Dividend yield | -- |
| Earnings growth (last year) | -173.08% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | +12.00% |
| Revenue growth (last year) | +43.97% |
| P/E ratio | 27.0 |
| Price/Sales | 5.15 |
| Price/Book | 6.90 |
| Today’s change | Today’s % change | |
|---|---|---|
| AGNAllergan Inc | +0.06 | +0.06% |
| ALXNAlexion Pharmaceutic... | -0.71 | -0.71% |
| SHPGShire PLC | +2.75 | +2.84% |
| VRTXVertex Pharmaceutica... | -0.08 | -0.10% |
| Next reporting date | August 8, 2013 |
| EPS forecast (this quarter) | -- |
| Annual revenue (last year) | $3.5B |
| Annual profit (last year) | -$116.0M |
| Net profit margin | -3.27% |
Sector Health Technology |
Industry Pharmaceuticals: Other |
Chairman & Chief Executive Officer J. Michael Pearson, MBA |
Chief Financial Officer, Director & Executive VP Howard Bradley Schiller |
Corporate headquarters Montréal, Québec |
.
